Therapy Areas: Oncology
FDA approval streamlines access to Bristol Myers Squibb CAR T cell therapies
27 June 2025 - Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced late Thursday that the US Food and Drug Administration has approved updated labels for its two CAR T cell therapies, ...
Porton Advanced signs MOU with EVA Pharma for expanded Middle East and Africa CAR T-cell therapy access
27 June 2025 - Porton Advanced Solutions, a US-based global cell and gene therapy CDMO service provider, and EVA Pharma, an Egypt-based pharmaceutical company, announced on Thursday the signing of Mem...
Biovica secures European patent for biomarker use in immuno-oncology
26 June 2025 - Biovica International AB (Nasdaq First North Premier Growth Market:BIOVIC-B), a supplier of blood-based biomarker assays to monitor cancer progression, revealed on Thursday that it has ...
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
26 June 2025 - CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a China-based company involved in developing innovative CAR T-cell therapies, announced on Wednesday that the National Medic...
Scancell expands Phase 2 SCOPE trial with new intradermal dosing arm for iSCIB1+
25 June 2025 - Scancell Holdings plc (AIM: SCLP), a developer of novel immunotherapy products to treat cancer, announced on Wednesday that it has commenced dosing in Cohort 4 of its Phase 2 SCOPE stud...
Telix Pharmaceuticals delivers first commercial doses from Belgian manufacturing hub
25 June 2025 - Biopharmaceutical company Telix Pharmaceuticals Limited (ASX: TLX) (NASDAQ: TLX) announced on Wednesday that its Telix Manufacturing Solutions (TMS) facility in Brussels South (Seneffe)...